Augmentation of clozapine with agomelatine in partial-responder schizophrenia: A 16-week, open-label, uncontrolled pilot study

Journal of Clinical Psychopharmacology

Volumn 34, Issue 4, 2014, Pages 491-494

  Bruno, Antonio ^a   Zoccali, Rocco A ^a   Abenavoli, Elisabetta ^a   Pandolfo, Gianluca ^a   Scimeca, Giuseppe ^a   Spina, Edoardo ^a   Muscatello, Maria Rosaria Anna ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

agomelatine; augmentation; clozapine; schizophrenia

Indexed keywords

AGOMELATINE; CLOZAPINE; ACETAMIDE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CALGARY DEPRESSION SCALE; CLINICAL ARTICLE; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; MENTAL DISEASE; MONOTHERAPY; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SOMNOLENCE; STROOP TEST; TREATMENT DURATION; TREATMENT RESPONSE; WISCONSIN CARD SORTING TEST; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; TREATMENT OUTCOME; YOUNG ADULT;

ACETAMIDES; ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PILOT PROJECTS; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903764571     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000157     Document Type: Article

References (35)

1. Leucht S, Cipriani A, Spinelli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951-962.
2. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res. 2002;56:1-10. (Pubitemid 34655461)
3. Tiihonen J, Leucht S. Clozapine resistance-augmentation strategies. Eur Neuropsychopharmacol. 2013;23:338.
4. Muscatello MR, Pandolfo G, Mico U, et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34:129-133.
5. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011;127:93-99.
6. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry. 2010;23:103-111.
7. Zoccali R, Muscatello MR, Bruno A, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res. 2007;93:109-116. (Pubitemid 46817934)
8. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009;109:10-14.
9. Afshar H, Roohafza H, Mousavi G, et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol. 2008;23:157-162.
10. Muscatello M, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol. 2011;25:667-674.
11. Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197:174-179.
12. Mico U, Bruno A, Pandolfo G, et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26:303-310.
13. Zoccali R, Muscatello MRA, Cedro C, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-bind, placebo-controlled study. Int Clin Psychopharmacol. 2004;19:71-76. (Pubitemid 38324586)
14. Chenu F, El Mansari M, Blier P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology. 2013;38:275-284.
15. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012;27:113-119.
16. Monteleone P, Natale M, La Rocca A, et al. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology. 1997;36:159-163. (Pubitemid 27472513)
17. Bersani G, Mameli M, Garavini A, et al. Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuro Endocrinol Lett. 2003;24:181-184. (Pubitemid 37074810)
18. Afonso P, Brissos S, Figueira ML, et al. Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep. Schizophr Res. 2010;120:227-228.
19. Park HJ, Park JK, Kim SK, et al. Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci. 2011;45:304-308.
20. Morera-Fumero AL, Abreu-Gonzalez P. Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression. J Clin Psychopharmacol. 2010;30:739-741.
21. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
22. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand. 2004;110:292-298. (Pubitemid 39278988)
23. Leucht S, Kane JM, Kissling W, et al. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187:366-371. (Pubitemid 41442390)
24. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems; 1986.
25. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;33:39-44. (Pubitemid 23355888)
26. Heaton R, Chelune G, Talley J, et al. Wisconsin Card Sorting Test Manual. Odessa, FL: Psychological Resources; 1993.
27. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 2nd ed. New York, NY: Oxford University Press; 1998.
28. Trenerry MR, Crosson B, DeBoe J, et al. Stroop Neuropsychological Screening Test. Odessa, FL: Psychological Assessment Resources Inc; 1989.
29. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64:1115-1122. (Pubitemid 47529336)
30. Bartels C, Wegrzyn M, Wiedl A, et al. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci. 2010;11:118 http://www.biomedcentral.com/ 1471-2202/11/118.
31. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
32. Leucht S, Davis JM, Engel RR, et al. Defining ''response'' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. 2007;32:1903-1910. (Pubitemid 47258518)
33. Fornaro M, Prestia D, Colicchio S, et al. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8:287-304.
34. Andreasen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449. (Pubitemid 40343909)
35. Spina E, Trifiro' G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26:39-67.